Your browser doesn't support javascript.
loading
Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis.
Van de Wyngaert, Zoé; Romera-Martinez, Irene; Chedeville, Céline; Musiu, Paolo; Ikhlef, Souhila; Jonca, Bénédicte; Mohty, Mohamad; Malard, Florent.
Affiliation
  • Van de Wyngaert Z; Sorbonne Université ; Centre de Recherche Saint-Antoine INSERM UMRs938.
  • Romera-Martinez I; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
  • Chedeville C; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
  • Musiu P; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
  • Ikhlef S; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
  • Jonca B; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
  • Mohty M; Service de médecine nucléaire Tenon Hospital.
  • Malard F; Sorbonne Université ; Centre de Recherche Saint-Antoine INSERM UMRs938.
Clin Hematol Int ; 6(2): 46-50, 2024.
Article in En | MEDLINE | ID: mdl-38817306
ABSTRACT
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Hematol Int Year: 2024 Document type: Article Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Hematol Int Year: 2024 Document type: Article Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM